Raymond James raised Johnson & Johnson's price target to $280, signaling a 10% upside from current levels. The boost follows strong Q2 revenue growth in its oncology division, which now accounts for nearly 29% of total revenues, driven by key cancer therapies. Positive analyst sentiment and the upcoming launch of the OTTAVA robotic surgical system highlight the company's growth potential and innovation in healthcare technology.
Johnson & Johnson has achieved its 64th consecutive year of dividend increases, raising its quarterly dividend by 3.1% to $1.34 per share in 2026. Despite strong overall sales growth driven by new drugs like Tremfya and Darzalex, the company faces si...
With market risks rising in October 2026, five elite dividend stocks in healthcare, consumer staples, and utilities are highlighted for their resilience during downturns. These stocks, including Coca-Cola, Johnson & Johnson, McDonald's, NextEra Energ...
Procter & Gamble leads with 70 years of consecutive dividend increases, joined by Johnson & Johnson, Coca-Cola, ADP, and Lowe's, each maintaining solid payout ratios and strong cash flow coverage. These companies demonstrate resilience through recess...
Johnson & Johnson and Procter & Gamble are both Dividend Kings with similar valuations, but Johnson & Johnson is favored for long-term dividend growth due to better dividend coverage, lower payout ratio, and stronger growth prospects despite P&G's lo...
